These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8432624)

  • 21. In vitro metabolism of cyclosporin A with rabbit renal or hepatic microsomes: analysis by HPLC-FPIA and HPLC-MS.
    Pham-Huy C; Sadeg N; Becue T; Martin C; Mahuzier G; Warnet JM; Hamon M; Claude JR
    Arch Toxicol; 1995; 69(5):346-9. PubMed ID: 7654141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of thyroxine on hyperkalemia and renal cortical Na+, K+ - ATPase activity induced by cyclosporin A.
    You CW; Park YH; Lee ES; Kim YJ; Shin SM; Park MO
    J Korean Med Sci; 2002 Oct; 17(5):625-32. PubMed ID: 12378013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
    Sun QL; Li M; Rui HL; Chen YP
    J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):301-10. PubMed ID: 25500744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporine effects on the antioxidant capacity of rat renal tissues.
    Ghaznavi R; Zahmatkesh M; Kadkhodaee M; Mahdavi-Mazdeh M
    Transplant Proc; 2007 May; 39(4):866-7. PubMed ID: 17524835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy.
    Duymelinck C; Deng JT; Dauwe SE; De Broe ME; Verpooten GA
    Kidney Int; 1998 Sep; 54(3):804-18. PubMed ID: 9734605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective suppression of rat hepatic microsomal activity during chronic cyclosporine nephrotoxicity.
    Brunner LJ; Bennett WM; Koop DR
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1710-8. PubMed ID: 8667242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporin A-induced changes in nitric oxide synthase activity in the rat kidney: in vitro and in vivo assay.
    Rao MR; Kanji VK; Setty VV; Wang C; Salahudeen AK; Das SK; Cohly HH
    Indian J Physiol Pharmacol; 1996 Apr; 40(2):183-5. PubMed ID: 9062818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of vitamin E and/or quercetin in attenuating chronic cyclosporine A-induced nephrotoxicity in male rats.
    Zal F; Mostafavi-Pour Z; Vessal M
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):720-4. PubMed ID: 17600547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accumulation of acidic renin isoforms in kidneys of cyclosporine-A-treated rats.
    Norling LL; Tufro-McReddie A; Ariel Gomez R; Moore LC; Kaskel FJ
    J Am Soc Nephrol; 1996 Feb; 7(2):331-7. PubMed ID: 8785405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
    Thomas SE; Andoh TF; Pichler RH; Shankland SJ; Couser WG; Bennett WM; Johnson RJ
    Kidney Int; 1998 Apr; 53(4):897-908. PubMed ID: 9551396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition.
    Gardner MP; Houghton DC; Andoh TF; Lindsley J; Bennett WM
    Transplantation; 1996 May; 61(10):1506-12. PubMed ID: 8633380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro metabolism of cyclosporine A by human kidney CYP3A5.
    Dai Y; Iwanaga K; Lin YS; Hebert MF; Davis CL; Huang W; Kharasch ED; Thummel KE
    Biochem Pharmacol; 2004 Nov; 68(9):1889-902. PubMed ID: 15450954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP4A/CYP2C modulation of the interaction of calcium channel blockers with cyclosporine on EDHF-mediated renal vasodilations in rats.
    Hammoud SH; Omar AG; Eid AA; El-Mas MM
    Toxicol Appl Pharmacol; 2017 Nov; 334():110-119. PubMed ID: 28899749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of low and high density lipoproteins on renal cyclosporine A and cyclosporine G disposition in the isolated perfused rat kidney.
    Strong ML; Ueda CT
    Pharm Res; 1997 Oct; 14(10):1466-71. PubMed ID: 9358563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An underlying role for hepatobiliary dysfunction in cyclosporine A nephrotoxicity.
    Aleo MD; Doshna CM; Fritz CA
    Toxicol Appl Pharmacol; 2008 Jul; 230(1):126-34. PubMed ID: 18407308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allicin ameliorates kidney function and urinary bladder sensitivity in cyclosporine A-treated rats.
    El-Kashef DH; El-Kenawi AE; Suddek GM; Salem HA
    Hum Exp Toxicol; 2017 Jul; 36(7):681-691. PubMed ID: 27596067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
    Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
    Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational control of insulin biosynthesis. Evidence for regulation of elongation, initiation and signal-recognition-particle-mediated translational arrest by glucose.
    Welsh M; Scherberg N; Gilmore R; Steiner DF
    Biochem J; 1986 Apr; 235(2):459-67. PubMed ID: 3017307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporin A inhibits prostaglandin E2 formation by rat mesangial cells in culture.
    Stahl RA; Adler S; Baker PJ; Johnson RJ; Chen YP; Pritzl P; Couser WG
    Kidney Int; 1989 May; 35(5):1161-7. PubMed ID: 2504985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.